Importantly, Ruxolitinib, originally discovered as a JAK inhibitor upstream of STAT3, was recently shown to possess CaMKII inhibitory properties and protect against ventricular arrhythmias (52). Here, CAMK2G is linked to Ventricular arrhythmia.